Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q1

9776.TEDINET S100OYM4
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥4.9bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥4.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥132m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥292m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥223m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥294m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥222m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥191m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥78m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥107m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥125m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥106m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥16.2bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥14.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2022-06-30Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.4bnat 2022-06-30Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.5bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.6bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥23.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥31.312021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio62.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.0%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥22m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥846,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥15m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥200m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥78m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥376m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥233m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥143m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥3m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥143m
—segment totalsegment profit2022-04-01 → 2022-06-30¥275m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥144m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥290m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥19m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥351,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30¥11m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥304m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥131m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥710m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥170m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥539m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥7m
—segment totalrevenue2021-04-01 → 2021-06-30¥5.2bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥4.6bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥539m
—segment totalsegment profit2021-04-01 → 2021-06-30¥442m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥5.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥4.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥540m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥453m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 380
ItemContextValueUnit
Other nclPrior1YearInstant6053000JPY
Other nclCurrentQuarterInstant5993000JPY
Noncurrent liabilitiesPrior1YearInstant2529694000JPY
Noncurrent liabilitiesCurrentQuarterInstant2470886000JPY
LiabilitiesPrior1YearInstant5811490000JPY
LiabilitiesCurrentQuarterInstant5821027000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant8812690000JPY
Retained earningsCurrentQuarterInstant8813684000JPY
Treasury stockPrior1YearInstant-728236000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10083073000JPY
Shareholders equityCurrentQuarterInstant10054853000JPY
Valuation difference on available for sale securitiesPrior1YearInstant31227000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant26454000JPY
Valuation and translation adjustmentsPrior1YearInstant31227000JPY
Valuation and translation adjustmentsCurrentQuarterInstant26454000JPY
Non controlling interestsPrior1YearInstant223659000JPY
Non controlling interestsCurrentQuarterInstant270779000JPY
Net assetsPrior1YearInstant10337959000JPY
Net assetsCurrentQuarterInstant10352086000JPY
Liabilities and net assetsPrior1YearInstant16149449000JPY
Liabilities and net assetsCurrentQuarterInstant16173114000JPY
Net salesPrior1YTDDuration4638812000JPY
Net salesCurrentYTDDuration4900050000JPY
Cost of salesPrior1YTDDuration3103187000JPY
Cost of salesCurrentYTDDuration3428989000JPY
Gross profitPrior1YTDDuration1535625000JPY
Gross profitCurrentYTDDuration1471061000JPY
Selling general and administrative expensesPrior1YTDDuration1243239000JPY
Selling general and administrative expensesCurrentYTDDuration1339384000JPY
Operating incomePrior1YTDDuration292385000JPY
Operating incomeCurrentYTDDuration131676000JPY
Interest income noiPrior1YTDDuration46000JPY
Interest income noiCurrentYTDDuration29000JPY
Dividends income noiPrior1YTDDuration3172000JPY
Dividends income noiCurrentYTDDuration2817000JPY
Rent income noiPrior1YTDDuration11554000JPY
Rent income noiCurrentYTDDuration11262000JPY
Subsidy income noi bountyPrior1YTDDuration－JPY
Subsidy income noi bountyCurrentYTDDuration87229000JPY
Other noiPrior1YTDDuration3175000JPY
Other noiCurrentYTDDuration4123000JPY
Non operating incomePrior1YTDDuration17948000JPY
Non operating incomeCurrentYTDDuration105462000JPY
Interest expenses noePrior1YTDDuration2233000JPY
Interest expenses noeCurrentYTDDuration2031000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass